LSN Management Team

Dennis Ford
Founder & CEO; Creator of RESI Conference Series

Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. Dennis has spent a decade in the early-stage life science arena creating a partnering platform that matches next-generation drugs, devices, diagnostics, and digital health products with investor and licensing partners. Dennis has developed an active network of global investors ranging from Family Offices, Private Equity, Venture Capital, Foundations, and Endowments to large Corporate and Pharmaceutical firms interested in high-growth early-stage technologies. Dennis has also pioneered a unique global partnering event called the Redefining Early-Stage Investments Conference Series that matches investors and licensing partners with startup firms based on stage of development and product.

Dennis is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive’s Fundraising Manifesto which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO’s which is now offered to help launch and fund startups into the global life science arena. Dennis is working on his fourth book, The Entrepreneur Elucidated, that is scheduled for a 2024 release.

William Kohlbrenner
Technical and Strategic Advisor, Life Science Nation

Dr. Kohlbrenner currently serves as a technical and strategic advisor at LSN where he supports a range of company initiatives, including the RESI conference series. Bill has been associated with LSN in several capacities since 2014 and was the company’s CSO from 2015 through 2021.

Dr. Kohlbrenner has had a long career in pharma/biotech where he led drug discovery research programs in several therapeutic areas, including oncology, antivirals and antibacterials at AbbVie. He also led a global scouting team that was involved in pursuing early-stage assets around the globe. After leaving AbbVie Bill was CEO of a Chicago based early-stage biotech focused on Alzheimer’s. More recently he was VP of Drug Development at BioLoomics, a CO-based technology company with an AI-driven platform for discovering novel antibody cancer drugs, where he is now a company advisor.

Bill has co-authored numerous research articles (~60) examining the fundamental aspects of various drug targets and the molecular basis of drug action. He received his Ph.D. from the State University of New York (SUNY) and completed postdoctoral training at the Molecular Biology Institute at UCLA.